A Phase <scp>II</scp> Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis
Roy Fleischmann(The University of Texas Southwestern Medical Center), Marc C. Levesque(AbbVie (United States)), Francisco J. Blanco(Instituto de Investigación Biomédica de A Coruña), Lanju Zhang(AbbVie (United States)), Thomas J. Schnitzer, Johanne Martel‐Pelletier(Centre Hospitalier de l’Université de Montréal), Gurjit S. Kaeley(University of Florida), Matthew P. Kosloski(AbbVie (United States)), Francis Bérenbaum(Inserm), Li Wang(AbbVie (United States)), Wei Liu(AbbVie (United States)), Philip G. Conaghan(University of Leeds), Su Chen(First Affiliated Hospital of Xi'an Jiaotong University), Sheng Feng(AbbVie (United States)), Charles G. Peterfy(Boca Raton Regional Hospital), Ole Vaeterlein(BioClinica (United States)), G Levy(AbbVie (United States)), Jean‐Pierre Pelletier(Centre Hospitalier de l’Université de Montréal), Henning Bliddal(University of Copenhagen)
Cited by 209
Related Papers
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
|New England Journal of Medicine|2000|4k
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
|New England Journal of Medicine|2000|1.8k
EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis
|Annals of the Rheumatic Diseases|2013|1.4k
Clopidogrel with or without Omeprazole in Coronary Artery Disease
|New England Journal of Medicine|2010|1.2k